User profiles for "author:Despina Eleftheriou"
Despina EleftheriouVerified email at ucl.ac.uk Cited by 5434 |
European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease–the SHARE initiative
N de Graeff, N Groot, S Ozen, D Eleftheriou… - …, 2019 - academic.oup.com
Abstract Objectives The European Single Hub and Access point for paediatric
Rheumatology in Europe initiative aimed to optimize care for children with rheumatic …
Rheumatology in Europe initiative aimed to optimize care for children with rheumatic …
Medium-size-vessel vasculitis
MJ Dillon, D Eleftheriou, PA Brogan - Pediatric Nephrology, 2010 - Springer
Medium-size-artery vasculitides do occur in childhood and manifest, in the main, as
polyarteritis nodosa (PAN), cutaneous PAN and Kawasaki disease. Of these, PAN is the …
polyarteritis nodosa (PAN), cutaneous PAN and Kawasaki disease. Of these, PAN is the …
Small vessel vasculitis
P Brogan, D Eleftheriou, M Dillon - Pediatric Nephrology, 2010 - Springer
The pediatric small vessel vasculitides reviewed in this article are Henoch–Schönlein
purpura (HSP) and the anti-neutrophil cytoplasmic antibody-associated vasculitides (AAV) …
purpura (HSP) and the anti-neutrophil cytoplasmic antibody-associated vasculitides (AAV) …
Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease
Objective: To assess the utility and safety of rituximab in pediatric autoimmune and
inflammatory disorders of the CNS. Methods: Multicenter retrospective study. Results: A total …
inflammatory disorders of the CNS. Methods: Multicenter retrospective study. Results: A total …
Deficiency of adenosine deaminase type 2: a description of phenotype and genotype in fifteen cases
S Nanthapisal, C Murphy, E Omoyinmi… - Arthritis & …, 2016 - Wiley Online Library
Objective To describe the clinical features, genotype, and treatment in a series of subjects
with confirmed adenosine deaminase 2 (ADA2) deficiency. Methods All symptomatic …
with confirmed adenosine deaminase 2 (ADA2) deficiency. Methods All symptomatic …
Anti-neutrophil cytoplasmic antibodies stimulate release of neutrophil microparticles
Y Hong, D Eleftheriou, AAK Hussain… - Journal of the …, 2012 - journals.lww.com
The mechanisms by which anti-neutrophil cytoplasmic antibodies (ANCAs) may contribute to
the pathogenesis of ANCA-associated vasculitis are not well understood. In this study, both …
the pathogenesis of ANCA-associated vasculitis are not well understood. In this study, both …
The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of …
K Cetin Gedik, L Lamot, M Romano… - Arthritis & …, 2022 - Wiley Online Library
Objective Autoinflammatory type I interferonopathies, chronic atypical neutrophilic
dermatosis with lipodystrophy and elevated temperature/proteasome‐associated …
dermatosis with lipodystrophy and elevated temperature/proteasome‐associated …
Biologic therapy in refractory chronic non-bacterial osteomyelitis of childhood
D Eleftheriou, T Gerschman, N Sebire, P Woo… - …, 2010 - academic.oup.com
Objective. To date there is no uniformly effective treatment for either chronic recurrent
multifocal osteomyelitis (CRMO) or synovitis, acne, pustulosis, hyperostosis and osteitis …
multifocal osteomyelitis (CRMO) or synovitis, acne, pustulosis, hyperostosis and osteitis …
Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS)
P Dolezalova, FE Price-Kuehne, S Özen… - Annals of the …, 2013 - ard.bmj.com
Background Rare chronic childhood vasculitides lack a reliable disease activity assessment
tool. With emerging new treatment modalities such a tool has become increasingly essential …
tool. With emerging new treatment modalities such a tool has become increasingly essential …
Autoinflammatory periodic fever, immunodeficiency, and thrombocytopenia (PFIT) caused by mutation in actin-regulatory gene WDR1
The importance of actin dynamics in the activation of the inflammasome is becoming
increasingly apparent. IL-1β, which is activated by the inflammasome, is known to be central …
increasingly apparent. IL-1β, which is activated by the inflammasome, is known to be central …